We are live on ! Find out more
IPSC icon

Century Therapeutics

56 hedge funds and large institutions have $183M invested in Century Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

130% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 10

8% more funds holding

Funds holding: 5256 (+4)

0.69% less ownership

Funds ownership: 37.66%36.97% (-0.69%)

34% less capital invested

Capital invested by funds: $279M → $183M (-$96.1M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
0.94%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
23
Reduced
10
Closed
3
Calls
Puts
Net Calls
Net Calls Change

IPSC Hedge Fund Activity: Q2 2022 in Review

56 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q2 2022, worth a combined $183M — down 34% from $279M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IPSC positions and 3 closed out — a net gain of 6 holders — while 23 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $2.73M. The largest seller was Fidelity Investments, cutting an estimated $6.4M.

  • 56 institutional investors held Century Therapeutics (IPSC) as of Q2 2022, up from 52 in Q1 2022.
  • Funds reported $183M of Century Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
  • 9 funds opened new Century Therapeutics positions in Q2 2022 and 3 closed out, a net change of +6 holders.
  • The largest Century Therapeutics buyer in Q2 2022 was BlackRock, an estimated $2.73M added.
  • The largest Century Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $6.4M sold.

Based on aggregated 13F filings for Q2 2022.